Quantcast

Sustained Release Injectables to 2020

February 11, 2014

DUBLIN, Feb. 11, 2014 /PRNewswire/ –

Research and Markets

(

http://www.researchandmarkets.com/research/5nldqw/sustained_release

) has announced the addition of the

“Sustained Release Injectables to 2020″

report to their offering.


(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Formulations, Dosing, Devices, Markets and Forecasts




The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs. Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug’s release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase.




Highlights


    --  Provides detailed analysis of sustained release injectable products,
        market segments, market dynamics and market demographics
    --  Analyzes therapeutic demand drivers and evaluates commercial sustained
        release injectables in eleven major therapeutic segments
    --  Charts sustained release product data and market share, and provides
        forecasts to 2020
    --  Profiles sustained release technology participants, their product
        development activities, business strategies, and corporate alliances and
        affiliations

Key Topics Covered:



Executive Summary



Injectable Drug Market Dynamics



The Trend toward Self-Administration

Shifting Demographics

Injectable Drug Formulation Technology

Innovation in Injectable Device Designs

Therapeutic Demand Drivers

Competitive Landscape

Risk Factors



Sustained Release Injectables – Branded Formulation Technologies



Biodegradable Polymers

PEG

PLG/PLA/PLGA

Polyether ester

Branded SR Formulation Technologies

ChroniJect

CriticalMix

Depofoam

LinkeRx

Liposomes

Medisorb

Medusa

Optisomes

OxtoDEX

SABER/SAIB

SynBiosys

Supercritical Fluid



Approved Sustained Release Injectables by Therapeutic Indication



Acromegaly

lanreotide acetate

octreotide acetate

Hormone Therapy

Medroxyprogesterone

Somatropin

Infectious Disease

Interferon

Metabolic

Exenatide

Oncology

Neoplastic Meningitis

Cytarabine

Prostate

leuprolide acetate

leuprolide acetate

triptorelin pamoate

Schizophrenia

Fluphenazine

Haloperidol

paliperidone palmitate

olanzapine

risperidone

Substance Abuse

naltrexone

Reproductive Health

Estradiol valerate

Depo-estradiol

Depo-testosterone



Development-Stage SR Injectable Drug Candidate Assessment



Addiction

Antivirals

Hormones

Immune Modulators

Incretin Mimetics

Local Anesthetics

Opioid Antagonists

Psychotropics

Antineoplastics





SR Injectables – Therapeutic Sector Impact Analysis & Forecasts



Addiction

Autoimmune Diseases

Diabetes

Infectious Disease

Macular Degeneration

Metabolic Diseases

Neurology

Oncology

Pain Management

Reproductive Health



Sustained Release Injectables – Company Profiles



For more information visit http://www.researchandmarkets.com/research/5nldqw/sustained_release

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets


Source: PR Newswire



comments powered by Disqus